Butt, Jawad H; Nicolau, Jose Carlos 
; Verma, Subodh; Docherty, Kieran F; Petrie, Mark C; Inzucchi, Silvio E; Schou, Morten; Kosiborod, Mikhail N; Langkilde, Anna Maria; Martinez, Felipe A
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, GLICOSÍDEOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H et al. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, v. 23, n. 4, p. 601-613, 2021Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2124. Acesso em: 10 jun. 2024.APA
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., et al. (2021). Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, 23( 4), 601-613. doi:10.1002/ejhf.2124NLM
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1002/ejhf.2124Vancouver
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1002/ejhf.2124
